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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPER2461Is “Sick Fat” a Cardiovascular Disease?Harold E. Bays
Adiposopathy (“adipose-opathy”) or “sick fat” is the term to describe the pathologic endocrine
and immune derangements caused by obesity. Bays reviews the evidence that adiposopathy
directly contributes to cardiovascular disease (CVD) through pericardiac and perivascular
effects and indirectly by worsening CVD risk factors. This review: 1) provides a historical
perspective of the pathogenic potential of adipose tissue; 2) describes the relationships
between adipose tissue and cardiovascular medicine; 3) outlines the anatomical, functional,
endocrine, and immune manifestations of adiposopathy; and 4) describes the importance of
interactions of adipose tissue with other body tissues.CLINICAL RESEARCH INTERVENTIONAL CARDIOLOGY
2474Platelet Reactivity After 1 Month of Clopidogrel
Is the Strongest Predictor of Adverse Outcomes Post-PCIGianluca Campo, Giovanni Parrinello, Paolo Ferraresi, Barbara Lunghi, Matteo Tebaldi, Matteo Miccoli,
Jlenia Marchesini, Francesco Bernardi, Roberto Ferrari, Marco Valgimigli
Campo and colleagues investigated temporal patterns of on-clopidogrel platelet reactivity (PR)
and its relationship with genotype and clinical outcomes after percutaneous coronary
intervention (PCI). On-clopidogrel PR was assessed with the VerifyNow P2Y12 assay
(Accumetrics Inc., San Diego, California) before PCI and at 1 and 6 months later. The
incidence of high on-clopidogrel PR decreased significantly from baseline at 1 and 6 months,
with 75 of 83 initially poor responders developing a normal response. Genotype data,
including CYP2C19*2 and *17 status, explained 8% of this trend. On-clopidogrel PR at 1
month was the best predictor of ischemic and bleeding events.
Editorial Comment: Dominick J. Angiolillo, p. 2484(continued on page A-24)
JUNE 21, 2011 (continued) A-24HEART FAILURE2487Good Outcomes With HeartMate II LVAD in Elderly PatientsRobert M. Adamson, Marcia Stahovich, Suzanne Chillcott, Sam Baradarian, Joseph Chammas, Brian Jaski,
Peter Hoagland, Walter Dembitsky
The HeartMate II (HM II, Thoractec Corporation, Pleasanton, California) left ventricular
assist device (LVAD) has been approved for destination therapy for patients with advanced
heart failure who are not candidates for transplantation. Adamson and colleagues compared
the outcomes of HM II LAVD recipients who were older or younger than 70 years of age to
determine if age should be a contraindication to LVAD therapy. There was no difference in
1-month, 1-year, or 2-year survival, and there were no differences in length of stay or other
adverse events in the 55 patients analyzed. These results show that advanced age should not
be used as an independent contraindication for LVAD therapy.ATRIAL FIBRILLATION2496Plasma vWF May Be a Useful Biomarker in Anticoagulated AF PatientsVanessa Rolda´n, Francisco Marı´n, Begoña Muiña, Jose Miguel Torregrosa, Diana Herna´ndez-Romero,
Mariano Valdés, Vicente Vicente, Gregory Y. H. Lip
Rolda´n and colleagues evaluated the prognostic value of von Willebrand factor (vWF) levels
in anticoagulated, permanent atrial fibrillation (AF) patients. All patients were stabilized on
oral anticoagulation therapy (international normalized ratios 2.0 to 3.0) prior to enrollment.
High vWF levels (221 IU/ml) were associated with future adverse cardiovascular events,
mortality, and major bleeding. vWF levels added valuable prognostic information to widely
used clinical risk stratification schema for stroke (CHADS2, CHA2DS2-VASc) and bleeding
(HAS-BLED). This biomarker of endothelial health may be useful for predicting stroke and
bleeding risks in patients with AF.Editorial Comment: Victor L. Serebruany, p. 2505CARDIAC IMAGING2507PET Imaging Shows Inflamed Valve Leaflets in Patients With ASGergana Marincheva-Savcheva, Sharath Subramanian, Sadia Qadir, Amparo Figueroa, Quynh Truong,
Jayanthi Vijayakumar, Thomas J. Brady, Udo Hoffmann, Ahmed Tawakol
Marincheva-Savcheva and colleagues collected data from patients who had both an
echocardiogram and 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)
imaging to determine if FDG uptake in the aortic valve (AV) is increased in patients with
aortic stenosis (AS). The AV PET signal was increased in patients with AS compared with
controls, particularly in those with mild or moderate stenosis. These observations support the
hypothesis that AS is an active inflammatory condition and provide a novel method to
evaluate the pathobiological processes involved in AS.(continued on page A-26)
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tCARDIAC IMAGING25162D Intravascular NIRF Molecular Imaging of AtherosclerosisFarouc A. Jaffer, Marcella A. Calfon, Amir Rosenthal, Georgios Mallas, R. Nika Razansky, Adam Mauskapf,
Ralph Weissleder, Peter Libby, Vasilis Ntziachristos
Jaffer and colleagues describe their effort to develop a 2-dimensional (2D) intravascular near-
infrared fluorescence (NIRF) imaging system for visualizing arterial inflammation in
coronary-sized vessels. A rotational, automated pullback catheter was optimized for 360°
intravascular NIRF imaging. Imaging of coronary artery-scaled phantoms demonstrated
submillimeter axial resolution and nanomolar sensitivity to near-infrared fluorochromes. In
the future, high-resolution molecular imaging of coronary arteries may help us to understand
the natural history of inflammation in a variety of coronary arterial pathologies as well as the
response to novel pharmacotherapies.PRE-CLINICAL RESEARCH PRE-CLINICAL RESEARCH2527PDGF-Dependent PI 3-Kinase and PLC Activation Linked to Neointima FormationEvren Caglayan, Marius Vantler, Olli Leppänen, Felix Gerhardt, Lenard Mustafov, Henrik ten Freyhaus,
Kai Kappert, Margarete Odenthal, Wolfram H. Zimmermann, Michelle D. Tallquist, Stephan Rosenkranz
Platelet-derived growth factor (PDGF) is a potent mitogen and chemoattractant for vascular
smooth muscle cells (VSMC) and may stimulate neointima formation. Caglayan and
colleagues studied the signaling pathways that control platelet-derived growth factor-
receptor (PDGFR)–driven VSMC proliferation and migration by creating specific
utations in the receptor. The results showed that the chemotactic response and the stimulus
o proliferation require the activation of PI3K and PLC. Disruption of these pathways in
mice led to a profound reduction of neointima formation after balloon injury. These results
suggest potential targets for reducing neointima formation.
